AbbVie has agreed to pay $1.4 billion to buy Aliada Therapeutics. The acquisition will give AbbVie control of an Alzheimer’s ...

The purchase of Aliada Therapeutics is “interesting for a number of reasons,” according to a Stifel analyst, one of which is ...

U.S. drugmaker AbbVie said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental ...

The acquisition of Aliada Therapeutics will grant AbbVie access to a neuroscience-focused technology platform and an ...

The acquisition will allow AbbVie to accelerate development of ALIA-1758, a potential disease-modifying therapy for Alzheimer ...

AbbVie has entered a definitive agreement to acquire all outstanding equity of Aliada Therapeutics in a deal valued at $1.4bn ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its ...

The purchase is the latest in a slew of efforts to invest in its neuroscience portfolio as Humira faces generic competition.

The story with AbbVie (NYSE: ABBV) in 2024 is that it fell off a patent cliff but survived. It survived and continues to ...

The acquisition of Aliada Therapeutics gives AbbVie access to a Phase I anti-amyloid antibody as well as the biotech’s novel ...

AbbVie (ABBV) to acquire Aliada Therapeutics for $1.4B in cash, enhancing focus on Alzheimer's disease with innovative ...

AbbVie will buy Aliada Therapeutics for $1.4 billion in cash, it said on Monday, gaining access to the privately held therapy developer's Alzheimer's disease candidate as the U.S. drugmaker increases ...